Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$4.52
+0.2%
$4.12
$1.80
$20.83
$19.15M-0.791.10 million shs51,672 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$3.23
+2.9%
$3.31
$2.68
$7.90
$17.28M1.332,963 shs41,372 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.50
+7.6%
$1.64
$1.35
$53.79
$18.24M-0.07200,092 shs77,470 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$1.27
+4.1%
$1.75
$1.09
$14.83
$4.14M1.87961,498 shs186,983 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
+2.04%+8.94%+3.44%+22.55%+1,135.62%
Lipocine Inc. stock logo
LPCN
Lipocine
+0.96%-1.57%0.00%+2.45%-57.77%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
+2.21%-3.47%-26.84%-17.75%-92.68%
Soligenix Inc. stock logo
SNGX
Soligenix
+8.93%-13.48%-36.79%-37.44%-39.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cingulate Inc. stock logo
CING
Cingulate
2.7212 of 5 stars
3.54.00.00.01.11.70.6
Lipocine Inc. stock logo
LPCN
Lipocine
1.5767 of 5 stars
3.53.00.00.00.00.00.6
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.0353 of 5 stars
3.14.00.00.00.01.70.6
Soligenix Inc. stock logo
SNGX
Soligenix
1.6572 of 5 stars
0.05.00.00.03.00.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cingulate Inc. stock logo
CING
Cingulate
3.00
Buy$26.00475.22% Upside
Lipocine Inc. stock logo
LPCN
Lipocine
3.00
Buy$9.00178.64% Upside
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17713.82% Upside
Soligenix Inc. stock logo
SNGX
Soligenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SNGX, QTTB, LPCN, and CING Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/10/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/29/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$8.00
5/27/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $61.00
5/19/2025
Cingulate Inc. stock logo
CING
Cingulate
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$12.00 ➝ $11.00
4/21/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $60.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A$2.32 per shareN/A
Lipocine Inc. stock logo
LPCN
Lipocine
$11.20M1.54N/AN/A$3.93 per share0.82
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.16M15.72N/AN/A$0.47 per share3.18
Soligenix Inc. stock logo
SNGX
Soligenix
$120K34.50N/AN/A$1.64 per share0.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cingulate Inc. stock logo
CING
Cingulate
-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)
Lipocine Inc. stock logo
LPCN
Lipocine
$10K-$1.02N/AN/AN/A-26.68%-24.77%8/6/2025 (Estimated)
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)
Soligenix Inc. stock logo
SNGX
Soligenix
-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)

Latest SNGX, QTTB, LPCN, and CING Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.67-$1.06-$0.39-$1.06N/AN/A
5/8/2025Q1 2025
Cingulate Inc. stock logo
CING
Cingulate
-$1.00-$1.04-$0.04-$1.04N/AN/A
5/8/2025Q4 2024
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.35-$0.35N/A-$0.35$0.35 million$0.09 million
5/8/2025Q1 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.23-$0.90+$0.33-$0.90N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cingulate Inc. stock logo
CING
Cingulate
0.16
1.87
1.87
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
15.64
15.64
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
4.71
4.71
Soligenix Inc. stock logo
SNGX
Soligenix
N/A
1.85
1.85

Institutional Ownership

CompanyInstitutional Ownership
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%
Soligenix Inc. stock logo
SNGX
Soligenix
3.60%

Insider Ownership

CompanyInsider Ownership
Cingulate Inc. stock logo
CING
Cingulate
17.06%
Lipocine Inc. stock logo
LPCN
Lipocine
6.35%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
Soligenix Inc. stock logo
SNGX
Soligenix
3.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cingulate Inc. stock logo
CING
Cingulate
204.25 million3.52 millionNot Optionable
Lipocine Inc. stock logo
LPCN
Lipocine
105.35 million5.01 millionNo Data
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A
Soligenix Inc. stock logo
SNGX
Soligenix
203.26 million3.16 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cingulate stock logo

Cingulate NASDAQ:CING

$4.52 +0.01 (+0.22%)
As of 02:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Lipocine stock logo

Lipocine NASDAQ:LPCN

$3.23 +0.09 (+2.87%)
As of 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$1.50 +0.11 (+7.55%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$1.27 +0.05 (+4.10%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.